More isn't always better. Our Landkmarks of OncoPharm series covers lessons learned from the ProMACE-CytaBOM regimen for NHL.

ProMACE-CytaBOM: https://www.annalsofoncology.org/article/S0923-7534(20)31592-1/pdf

RCT vs. CHOP (& others): https://www.nejm.org/doi/full/10.1056/NEJM199304083281404

A brief overview of testicular cancer

A few supportive care updates:

1. Skin prophylaxis to prevent severe dermatologic toxicity with Nivo/Ipi.

Note* published in JCO Oncology Practice (NOT JAMA Oncol as stated in the episode

Link: https://doi.org/10.1200/OP-25-00100

2. Stampede-Metformin and how metformin has some beneficial effects in prostate cancer patients who don't have diabetes

Link: https://doi.org/10.1016/S1470-2045(25)00231-1

Two new drug approvals to talk about (after I misplaced my notes!)

Antiandrogen withdrawal is an historically well described phenomenon where prostate cancer patients experience PSA responses AFTER stopping their anti-androgen. But does this happen with today's 2nd generation antiandrogens?

A plethora of recent updates:

-Pembrolizumab (perioperative) in head & neck cancer (Keynote-689)

-Prostate cancer updates on cabozantinib/atezolizumab (yes, really) and talazoparib

-Pirtobrutinib improves PFS in CLL

-Zanubrutinib has a new dosage form on the way

-Another mitomycin product approved with "reverse thermal properties"

-A new regimen for FL of tafasitamab/rituximab/lenalidomide

-A comparison of the new ROS1-inhibitor, taltrectenib, compared to other 1st-line treatment options

A recap of notable updates from ASCO 2025

1. Destiny-Breast09

2. BREAKWATER

3. ATOMIC

4. Delphi-304

5. CM 816 OS update

6. C-POST

7. Matterhorn

Our Landmarks of OncoPharm series returns to discuss the CLEOPATRA study, which established docetaxel, trastuzumab, pertuzumab (THP) as a standard first-line regimen for metastatic HER2-amplified breast cancer.

If you've been struggling with how to talk to patients about ivermectin for cancer, then this podcast is for you.

1. Cancer misinformation on social media (Loeb, et al): https://doi.org/10.3322/caac.21857

2. Clinician communication with patients about cancer misinformation (Bylund, et al): https://doi.org/10.1200/OP.22.00526

Discussing recent FDA approvals of penpulimab, avutometenib, defactinib, and telisotuzumab vedotin.